Altimmune posts higher than expected Q3 loss 

By Reuters News


Overview

  • US biopharma firm's Q3 net loss and loss per share missed analyst expectations

  • Company ended Q3 with $480 mln in cash, cash equivalents and investments

  • Higher R&D and G&A expenses driven by clinical trials and compensation costs


Outlook

  • PERFORMA Phase 3 MASH trial progressing as planned; 52-week topline data readout expected in 2029

  • End-of-Phase 2 meeting with FDA for AUD program scheduled for December 2026

  • Topline data from RESTORE Phase 2 ALD trial expected in second half of 2027


Result Drivers

  • CLINICAL TRIAL SPENDING - Co said higher R&D expenses were primarily due to ongoing PERFORMA Phase 3 trial in MASH and RESTORE Phase 2 trial in ALD

  • COMPENSATION AND PROFESSIONAL SERVICES - Co said higher G&A expenses were mainly due to increased compensation expenses and professional services


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Loss Per Share

Miss

$0.15

$0.14 (9 Analysts)

Q3 Net Loss

Miss

$31.61 mln

$25.48 mln (8 Analysts)

Q3 Income from Operations

Miss

-$35.71 mln

-$28.42 mln (7 Analysts)

Q3 Loss Per Basic Share

$0.15

Q3 Operating Expenses

$35.71 mln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Altimmune, Inc. is $15.00, about 677.2% above its November 11 closing price of $1.93


Reuters Recommended Reads

  • Nov 10 - Tyra Biosciences Q3 net loss widens on higher R&D costs

  • Nov 9 - Trevi Therapeutics Q3 net loss widens on higher R&D costs

  • Nov 12 - Century Therapeutics Q3 net loss narrows, beats analyst expectations


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.